BCL2A1 is frequently highly expressed in hematologic malignancies and may contribute to the malignant phenotype, making ACC-1 and ACC-2 attractive targets for T cell immunotherapy (84, 85). This evidence concerns the gene BCL2A1 and adrenal cortex carcinoma.